Form 4: ARTL Director Converts Note to Warrants, Reinvests

ARTELO BIOSCIENCES Director Tamara A. Favorito converted a portion of a convertible promissory note into warrants and reinvested the remainder into a new note and additional warrants.

Summary

• Tamara A. Favorito, a Director of ARTELO BIOSCIENCES, INC. (ARTL), reported changes in her beneficial ownership.
• On October 28, 2025, a portion of a convertible promissory note, originally issued on May 1, 2025 (the "May Note"), with a value of $25,000, was automatically converted into a warrant (the "$6.24 Warrant").
• The $6.24 Warrant allows the purchase of 6,846 shares of Common Stock at an exercise price of $6.24 per share, expiring on October 28, 2030.
• On the same date, the remaining portion of the May Note was converted and reinvested into a new convertible note (the "October Note") and another warrant (the "$3.40 Warrant") through a Subscription Agreement.
• The October Note has a principal amount of $19,793 and is convertible into shares of Common Stock at the Reporting Person's discretion, expiring on April 28, 2026.
• The $3.40 Warrant allows the purchase of 12,566 shares of Common Stock at an exercise price of $3.40 per share, expiring on October 28, 2030.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the transaction involves potential future dilution from warrants and a convertible note, the director's decision to convert and reinvest indicates continued commitment and support for the company, which can be viewed favorably by investors. It also represents a restructuring of existing debt rather than an entirely new cash raise.

Positives

• The reinvestment by a director into a new convertible note and warrants demonstrates continued commitment and belief in the company's future prospects.
• The transaction represents a restructuring of existing debt, potentially providing the company with more flexible financing terms.

Negatives

• The issuance of new warrants and a convertible note introduces potential future dilution for existing shareholders if these instruments are converted or exercised.

Risks

• Future dilution risk for common stockholders if the $6.24 Warrant (6,846 shares), the $3.40 Warrant (12,566 shares), or the October Note ($19,793 principal amount) are converted or exercised.
• The company's reliance on convertible notes and warrants for financing may indicate ongoing capital needs.

Future Outlook

The October Note provides the Reporting Person with the right to convert its principal amount and accrued interest into shares of Common Stock at any time prior to payment in full, indicating potential future equity issuance. The warrants also represent future potential share issuance upon exercise.

Industry Context

This type of financing activity, involving convertible notes and warrants, is common for smaller biotechnology or pharmaceutical companies like ARTELO BIOSCIENCES, which often rely on such instruments to manage capital and fund research and development, especially when traditional debt or equity financing might be less accessible or more expensive.

Related Party Transactions

• The transaction involves a director of ARTELO BIOSCIENCES, INC. (Tamara A. Favorito) and the company, making it a related party transaction.

Stakeholder Impact

• Shareholders: Face potential future dilution if the convertible note is converted or the warrants are exercised, increasing the number of outstanding shares.
• Company: Benefits from the restructuring of debt and continued insider commitment, potentially strengthening its capital structure.

Next Steps

• Potential conversion of the October Note into Common Stock by the Reporting Person.
• Potential exercise of the $6.24 Warrant and the $3.40 Warrant by the Reporting Person.

Key Dates

Keywords

ARTELO BIOSCIENCES, ARTL, Form 4, Insider Transaction, Convertible Note, Warrant, Beneficial Ownership, Director, Equity Financing, Debt Restructuring